Sumitomo Pharma America receives USFDA approval of vibegron for benign prostatic hyperplasia

GEMTESA is the first and only beta-3 agonist approved for the treatment of men with OAB symptoms who are receiving pharmacological therapy for BPH

Ikena Oncology and Inmagene Biopharmaceuticals announce agreement for merger

The transaction is expected to result in approximately $175 million to support further development of IMG-007

MSD enters into license agreement with Hansoh Pharma for investigational Oral GLP-1 receptor agonist

USFDA approves Encorafenib plus Cetuximab and Chemo in BRAF V600E-positive mCRC

Accelerated approval is based on 61% overall response rate compared to 40% in control arm in the

Kenvue India presents report on ‘The Hydration Gap for Non-Diarrheal Illnesses’

The report also revealed that 87% of physicians agreed that FEE recommendations would help to improve the speed of recovery

Merck to acquire HUB Organoids to advance cell culture portfolio

Acquisition to advance company's next generation biology portfolio with internationally recognized pioneer in organoid development

Bayer announces positive topline resukts for Aflibercept 8 mg in phase III study

Demonstrates vision gains with extended treatment intervals in retinal vein occlusion

Rusan Pharma achieves GMP approvals from TGA (Australia) and ANVISA (Brazil) for its manufacturing facility in Kandla SEZ

The TGA approval marks a pivotal step in Rusan Pharma’s expansion into the Australian market

Merck announces FDA acceptance of biologics license application for Clesrovimab

An investigational long-acting monoclonal antibody designed to protect infants from RSV disease during their first RSV season

Jitendra Singh releases landmark RSSDI study ' Indian Prevention of Diabetes Study (IPDS) on Yoga and Diabetes Prevention'

A 40 minute daily Yoga routine, incorporating select asanas and pranayama, along with standard lifestyle interventions, can reduce the risk of developing diabetes by approximately 40%